394 related articles for article (PubMed ID: 19591631)
1. The PEPvIII-KLH (CDX-110) vaccine in glioblastoma multiforme patients.
Heimberger AB; Sampson JH
Expert Opin Biol Ther; 2009 Aug; 9(8):1087-98. PubMed ID: 19591631
[TBL] [Abstract][Full Text] [Related]
2. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma.
Sampson JH; Archer GE; Mitchell DA; Heimberger AB; Bigner DD
Semin Immunol; 2008 Oct; 20(5):267-75. PubMed ID: 18539480
[TBL] [Abstract][Full Text] [Related]
3. Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas.
Del Vecchio CA; Li G; Wong AJ
Expert Rev Vaccines; 2012 Feb; 11(2):133-44. PubMed ID: 22309662
[TBL] [Abstract][Full Text] [Related]
4. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients.
Paff M; Alexandru-Abrams D; Hsu FP; Bota DA
Hum Vaccin Immunother; 2014; 10(11):3322-31. PubMed ID: 25625931
[TBL] [Abstract][Full Text] [Related]
5. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines.
Schmittling RJ; Archer GE; Mitchell DA; Heimberger A; Pegram C; Herndon JE; Friedman HS; Bigner DD; Sampson JH
J Immunol Methods; 2008 Nov; 339(1):74-81. PubMed ID: 18775433
[TBL] [Abstract][Full Text] [Related]
6. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
Sampson JH; Heimberger AB; Archer GE; Aldape KD; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling RJ; Shi W; Vredenburgh JJ; Bigner DD
J Clin Oncol; 2010 Nov; 28(31):4722-9. PubMed ID: 20921459
[TBL] [Abstract][Full Text] [Related]
7. The EGFR variant III mutant as a target for immunotherapy of glioblastoma multiforme.
Chistiakov DA; Chekhonin IV; Chekhonin VP
Eur J Pharmacol; 2017 Sep; 810():70-82. PubMed ID: 28583430
[TBL] [Abstract][Full Text] [Related]
8. Prospect of rindopepimut in the treatment of glioblastoma.
Elsamadicy AA; Chongsathidkiet P; Desai R; Woroniecka K; Farber SH; Fecci PE; Sampson JH
Expert Opin Biol Ther; 2017 Apr; 17(4):507-513. PubMed ID: 28274144
[TBL] [Abstract][Full Text] [Related]
9. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme.
Sampson JH; Archer GE; Mitchell DA; Heimberger AB; Herndon JE; Lally-Goss D; McGehee-Norman S; Paolino A; Reardon DA; Friedman AH; Friedman HS; Bigner DD
Mol Cancer Ther; 2009 Oct; 8(10):2773-9. PubMed ID: 19825799
[TBL] [Abstract][Full Text] [Related]
10. Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.
Swartz AM; Li QJ; Sampson JH
Immunotherapy; 2014; 6(6):679-90. PubMed ID: 25186601
[TBL] [Abstract][Full Text] [Related]
11. Targeting EGFRvIII for glioblastoma multiforme.
Yang J; Yan J; Liu B
Cancer Lett; 2017 Sep; 403():224-230. PubMed ID: 28649003
[TBL] [Abstract][Full Text] [Related]
12. EGFRvIII-targeted vaccination therapy of malignant glioma.
Choi BD; Archer GE; Mitchell DA; Heimberger AB; McLendon RE; Bigner DD; Sampson JH
Brain Pathol; 2009 Oct; 19(4):713-23. PubMed ID: 19744042
[TBL] [Abstract][Full Text] [Related]
13. The epidermal growth factor variant III peptide vaccine for treatment of malignant gliomas.
Li G; Mitra S; Wong AJ
Neurosurg Clin N Am; 2010 Jan; 21(1):87-93. PubMed ID: 19944969
[TBL] [Abstract][Full Text] [Related]
14. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma.
Sampson JH; Aldape KD; Archer GE; Coan A; Desjardins A; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling R; Shi W; Vredenburgh JJ; Bigner DD; Heimberger AB
Neuro Oncol; 2011 Mar; 13(3):324-33. PubMed ID: 21149254
[TBL] [Abstract][Full Text] [Related]
15. Combination epidermal growth factor receptor variant III peptide-pulsed dendritic cell vaccine with miR-326 results in enhanced killing on EGFRvIII-positive cells.
Li J; Wang F; Wang G; Sun Y; Cai J; Liu X; Zhang J; Lu X; Li Y; Chen M; Chen L; Jiang C
Oncotarget; 2017 Apr; 8(16):26256-26268. PubMed ID: 28412740
[TBL] [Abstract][Full Text] [Related]
16. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma.
Babu R; Adamson DC
Core Evid; 2012; 7():93-103. PubMed ID: 23055947
[TBL] [Abstract][Full Text] [Related]
17. Emerging immunotherapies for glioblastoma.
Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
[TBL] [Abstract][Full Text] [Related]
18. Personalized neoantigen vaccines: a glimmer of hope for glioblastoma.
Londhe VY; Date V
Expert Rev Vaccines; 2020 May; 19(5):407-417. PubMed ID: 32238056
[TBL] [Abstract][Full Text] [Related]
19. Vaccination in the immunotherapy of glioblastoma.
Kong Z; Wang Y; Ma W
Hum Vaccin Immunother; 2018 Feb; 14(2):255-268. PubMed ID: 29087782
[TBL] [Abstract][Full Text] [Related]
20. Advances in Immunotherapy for Glioblastoma Multiforme.
Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]